Ding J, Vlahos C J, Liu R, Brown R F, Badwey J A
Boston Biomedical Research Institute, Massachusetts 02114, USA.
J Biol Chem. 1995 May 12;270(19):11684-91. doi: 10.1074/jbc.270.19.11684.
Several novel protein kinases are known to be rapidly activated in neutrophils stimulated with the chemoattractant fMet-Leu-Phe (fMLP). These kinases include a histone H4 protein kinase and several renaturable kinases with molecular masses of about 69, 63, 49, and 40 kDa. The renaturable kinases can catalyze the phosphorylation of a peptide that corresponds to residues 297-331 of the 47-kDa subunit of the NADPH-oxidase system (p47-phox). Previous studies have indicated that the activation of all of these protein kinases involves an uncharacterized stimulatory pathway and/or novel second messenger. The studies reported herein were undertaken to determine if phosphatidylinositol 3-kinase (PI3-K) is a component of this pathway. We report that certain chromosome derivatives (e.g. 2-(4-morpholinyl)-8-phenylchromone (LY294002)) and wortmannin, which inhibit PI3-K by distinct mechanisms, blocked activation of all of these novel kinases. These antagonists also inhibited the phosphorylation of p47-phox (about 50%) and O2.- release (about 80%) in cells stimulated with fMLP, but not with 4 beta-phorbol 12-myristate 13-acetate. A strong correlation exists between the amounts of these antagonists required to produce 50% inhibition of PI3-K in vitro and O2.- release in vivo. In contrast, a single atom substitution of LY294002 produced a compound (LY303511) that did not inhibit PI3-K. Compound LY303511 did not appreciably inhibit the activation of the novel protein kinases or O2.- generation. These data strongly suggest that PI3-K is involved in the activation of several novel protein kinases in neutrophils, one or more of which may be involved in O2.- release.
已知几种新型蛋白激酶在受趋化因子甲酰甲硫氨酰-亮氨酰-苯丙氨酸(fMLP)刺激的中性粒细胞中会迅速被激活。这些激酶包括一种组蛋白H4蛋白激酶和几种分子量约为69、63、49和40 kDa的可复性激酶。这些可复性激酶能催化一种与NADPH氧化酶系统47 kDa亚基(p47-phox)的297 - 331位残基相对应的肽段的磷酸化。先前的研究表明,所有这些蛋白激酶的激活都涉及一种未明确的刺激途径和/或新型第二信使。本文所报道的研究旨在确定磷脂酰肌醇3激酶(PI3-K)是否是该途径的一个组成部分。我们报告称,某些通过不同机制抑制PI3-K的染色体衍生物(如2-(4-吗啉基)-8-苯基色酮(LY294002))和渥曼青霉素,可阻断所有这些新型激酶的激活。这些拮抗剂还抑制了用fMLP刺激的细胞中p47-phox的磷酸化(约50%)和超氧阴离子(O₂⁻)释放(约80%),但对用4β-佛波醇12-肉豆蔻酸酯13-乙酸酯刺激的细胞没有影响。在体外产生50%抑制PI3-K所需的这些拮抗剂的量与体内O₂⁻释放之间存在很强的相关性。相比之下,LY294002的单原子取代产生了一种不抑制PI3-K的化合物(LY303511)。化合物LY303511没有明显抑制新型蛋白激酶的激活或O₂⁻的产生。这些数据有力地表明,PI3-K参与了中性粒细胞中几种新型蛋白激酶的激活,其中一种或多种可能参与O₂⁻释放。